Net revenue for the half year ended September 2020 reported at Rs 226.52 crore
Lincoln Pharmaceuticals has reported net profit of Rs 35.19 crore for the H1 FY21 ended September 2020 as against net profit of Rs 30.15 crore in the corresponding period last year, growth of 16.70 percent. Net revenue for the half year ended September 2020 reported at Rs 226.52 crore, higher by 8.05 percent over previous fiscal’s same period net revenue of Rs 209.64 crore. EBITDA for the half year ended September 2020 was reported at Rs 51.43 crore as compared to Rs 44.53 crore in the corresponding period last year. EPS was at
Rs 17.59 per share for H1 FY21 as compared to Rs 15.08 in the corresponding period last year. Lincoln Pharma has become a zero net-debt company by paying all its outstanding debt.
Commenting on the results and performance, Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “Company has delivered a robust operational and financial performance during the quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum. Exports sales (FOB) in Q2FY21 increased 9.65 percent to Rs 68.85 crore and is expected to get further boost once we start exports to Europe. Strategic growth initiatives, strong performance in the domestic and international markets, EU approval, new product approvals, better margin products along with operational efficiency are likely to contribute healthy growth and maximise value for all stakeholders in the near to medium term.”